Israel Englander Verve Therapeutics, Inc. Call Options Transaction History
Millennium Management LLC
- $207 Billion
- Q2 2024
Call Options
2 transactions
Others Institutions Holding VERV
# of Institutions
174Shares Held
74.8MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$72.5 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$38.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$30.9 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$26.6 Million0.01% of portfolio
-
State Street Corp Boston, MA3.35MShares$19.7 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $352M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...